Pharma Momentum Fuels Johnson & Johnson’s Path to Double-Digit Upside

The post Pharma Momentum Fuels Johnson & Johnson’s Path to Double-Digit Upside appeared first on 24/7 Wall St..

Our Johnson & Johnson (NYSE:JNJ) 24/7 Wall St. price target lands at $261.72, pointing to 11.28% upside from the current price of $235.18. Our recommendation is buy, and our model carries a 90% confidence level. JNJ has quietly become one of healthcare’s most reliable compounders again, with oncology firing and dividend support intact.

Metric	Value
Current Price	$235.18
24/7 Wall St. Price Target	$261.72
Upside	11.28%
Recommendation	BUY
Confidence Level	90%

A Quiet Rally Into New Highs

JNJ has run hard. Shares are up 14.91% year to date and 55.3% over the past year, currently trading about 1% below the 52-week high of $250.24. The latest Q1 2026 earnings report backed the move. Revenue rose 9.9% to $24.062 billion, and adjusted EPS of $2.70 beat estimates for the fourth consecutive quarter.

Management raised 2026 guidance to $100.3B to $101.3B in sales and $11.45 to $11.65 in adjusted EPS. Recent catalysts include a $1 billion Vision manufacturing expansion in Jacksonville, the $1 billion Firefly Bio acquisition adding a degrader-antibody-conjugate platform, and a Talvey late-stage trial showing up to 53% mortality risk reduction in multiple myeloma.

24/7 Wall St.

Why Bulls See a Breakout Toward $275

The bull case rests on oncology and immunology firing simultaneously. DARZALEX hit $3.964 billion (+22.5%), TREMFYA reached $1.608 billion (+68.3%), CARVYKTI grew 62.1%, and RYBREVANT/LAZCLUZE jumped 82.7%. Cardiovascular MedTech grew 13.0% on Abiomed and Shockwave.

The analyst consensus target of $252.87 sits between our base and our bull case of $273.48 over the next year. If the DePuy Synthes orthopaedics spin lifts the remaining mix toward double-digit growth, the multiple can expand from the current forward P/E of 20x.

The Risks Worth Watching

The bear case is real. STELARA fell 59.7% in Q1 on biosimilars, dragging Innovative Medicine by roughly 920 basis points. Litigation charges of $330 million in Q1 followed $854 million in Q4 2025, and talc cases remain an overhang.

Our bear scenario lands at $222.46, a 5.41% drawdown. That said, bulls would argue the headline net income decline of 52.4% reflects those non-recurring legal charges rather than underlying operating performance, where adjusted EPS still grew and guidance was raised.

Our Take on JNJ Here

The 24/7 Wall St. price target of $261.72 and buy rating reflect a balanced setup: defensive characteristics, accelerating top-line growth, and a pipeline that should outrun the STELARA cliff. The setup favors investors seeking healthcare exposure with a 0.26 beta and a 64-year dividend growth streak.

The case weakens if talc litigation reserves expand materially or if the orthopaedics separation slips beyond the 18 to 24 month window. Our 90% confidence is high for a reason: this is a low-volatility blue chip with a clear growth narrative.

JNJ Price Prediction 2026-2030

Looking further out, here is where our model projects Johnson & Johnson could trade, assuming current growth trajectories and the planned orthopaedics separation execute on schedule.

Year	24/7 Wall St. Price Target
2026	$248.24
2027	$273.86
2028	$294.53
2029	$315.88
2030	$333.63

These projections assume JNJ continues executing on oncology and cardiovascular MedTech. Significant upside or downside could result from talc litigation outcomes or the pace of double-digit growth promised by end of decade.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Johnson & Johnson didn’t make the cut. Grab the names FREE today.

The post Pharma Momentum Fuels Johnson & Johnson’s Path to Double-Digit Upside appeared first on 24/7 Wall St..